Description |
Product Type |
Product Size |
Injection |
1'S |
Product Company |
Roche Pharma |
Bevacizumab 400mg/16ml |
Product Type |
Product Size |
Injection |
1'S |
Product Company |
Roche Pharma |
Atezolizumab 1200mg/20ml |
Product Type |
Product Size |
Tablets |
30'S |
Product Company |
PMS Pharma |
Exemastane 25mg |
Product Type |
Product Size |
Injection |
1'S |
Product Company |
Roche Pharma |
Pertuzumab 420mg/14ml |
Product Type |
Product Size |
Tablet |
30'S |
Product Company |
Manufacture Deva Holding / Marketed by Searle |
Letrozole 2.5mg |
Product Type |
Product Size |
Injection |
1'S |
Product Company |
Roche Pharma |
Trastuzumab 600mg/5ml |
Content | "
Bevacizumab is a type of targeted cancer drug treatment. It is also known as Avastin. It is a treatment for a number of different cancer types. | "
Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer, hepatocellular carcinoma, and alveolar soft part sarcoma. | Exemestane is used to treat early breast cancer in women who have experienced menopause ('change of life'; end of monthly menstrual periods). | "
Pertuzumab is a monoclonal antibody. . Monoclonal antibodies work by attaching to proteins on or in cancer cells. Human epidermal growth factor 2 (HER2) is a protein that makes cells grow and divide. | Letrozole is a non-steroidal type II aromatase inhibitor. It blocks the active site, and therefore the electron transfer chain of CYP19A1. This competitive inhibition prevents the conversion of androgens to estrogen. This action leads to a reduction in uterine weight and elevated leuteinizing hormon. | Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. |
Reviews
There are no reviews yet.